The permeability and the efflux of alkaloids of the evodiae fructus in the caco-2 model

Phytotherapy Research

Volumn 23, Issue 1, 2009, Pages 56-60

  Yang, Xiu Wei ^a   Teng, Jie ^a,b   Wang, Ying ^a   Xu, Wei ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Caco 2 cells; Dehydroevodiamine; Evodiamine; Rutaecarpine; Wuzhuyurutine b

Indexed keywords

ALKALOID; DEHYDROEVODIAMINE; EVODIA FRUIT; EVODIAMINE; MANNITOL; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; PROPRANOLOL; RUTAECARPINE; UNCLASSIFIED DRUG; WUZHUYURUTINE;

ARTICLE; CARCINOMA CELL; CELL STRAIN CACO 2; COLON ADENOCARCINOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INTESTINE ABSORPTION; MONOLAYER CULTURE; PARAMETER; PERMEABILITY; ULTRAVIOLET RADIATION;

ALKALOIDS; BIOLOGICAL TRANSPORT, ACTIVE; CACO-2 CELLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EVODIA; HUMANS; INDOLE ALKALOIDS; INTESTINAL ABSORPTION; PERMEABILITY; PLANT EXTRACTS; QUINAZOLINES;

EID: 58149496654     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.2555     Document Type: Article

References (37)

1. Ahn SH, Jeon SH, Tsuruo T, Shim CK, Chung SJ. 2004. Pharmacokinetic characterization of dehydroevodiamine in the rat brain. J Pharm Sci 93: 283-292.
2. Chiou WF, Liao JF, Chen CF. 1996. Comparative study of the vasodilatory effects of three quinazoline alkaloids isolated from Evodia rutaecarpa. J Nat Prod 59: 37 4-378.
3. Choi YH, Shin EM, Kim YS, Cai XF, Lee JJ, Kim HP. 2006. Anti-inflammatory principles from the fruits of Evodia rutaecarpaand their cellular action mechanisms. Arch Pharm Res 29: 293-297.
4. Chong S, Dando SA, Morrison RA. 1997. Evaluation of biocoat intestinal epithelium differentiation environment (3-day cultured Caco-2 cells) as an absorption screening model with improved productivity. Pharm Res 14: 1835-1837.
5. Crowe A. 2002. The influence of P-glycoprotein on morphine transport in Caco-2 cells, comparison with paclitaxel. Eur J Pharmacol 440: 7-16.
6. Decker M. 2005. Novel inhibitors of acetyl- and butyrylcholine-sterase derived from the alkaloids dehydroevodiamine and rutaecarpine. Eur J Med Chem 40: 305-303.
7. Fei XF, Wang BX, Takashi I. 2002. Studies on evodiamine induced Hela cell apoptosis. Acta Pharm Sin 37: 673-676.
8. Gan LSL, Thakker DR. 1997. Application of the Caco-2 model in the design and development of orally active drugs: Elucidation of biochemical and physical barriers posed by the intestinal epithelium. Adv Drug Delivery Res 23: 77-98.
9. Gao J, Hugger ED, Beck-Westermeyer MS, Borchardt RT. 2000. Current Protocols in Pharmacology. John Wiley & Sons: Chichester; 7.2.1-7.2.23.
10. Heijn M, Hooijberg JH, Scheffer GL, Szabo G, Westerhoff HV, Lankelma J. 1997. Anthracyclines modulate multidrug resistance protein (MRP) mediated organic anion transport. Biochim Biophys Acta 1326: 12-22.
11. Hu CP, Xiao L, Deng HW, Li YJ. 2002. The cardioprotection of rutaecarpine is mediated by endogenous calcitonin related-gene peptide through activation of vanilloid receptors in guinea-pig hearts. Planta Med 68: 705-709.
12. Jedlitschky G, Leier I, Buchholz U. 1994. ATP-dependent transport of glutathine S-conjugates by the multidrug resistance-associated protein. Cancer Res 54: 4833-4836.
13. Jeng KF, Lin YH, Lin LC, Chou CJ, Tsai TH, Chen CF. 1995. High-performance liquid chromatographic determination of evodiamine in rat plasma: application to pharmacokinetic studies. J Chromatogr B Biomed Appl 668: 343-345.
14. Kobayashi Y. 2003. The nociceptive and anti-nociceptive effects of evodiamine from fruits of Evodia rutaecarpine in mice. Planta Med 69: 425-428.
15. Kobayashi Y, Nakano Y, Kizaki M, Hoshikuma K, Yokoo Y, Kamiya T. 2001. Capsaicin-like anticobese activities of evoidamine from fruits of Evoida rutaecarpa, a vanilloid receptor agonist. Planta Med 67: 628-633.
16. Komatsu K, Wakame K, Kamo Y. 1993. Pharmacological properties of galenical preparation pharmacokinetics of evo-diamine and the metabolite in rats. Biol Pharm Bull 16: 935-938.
17. Lee SK, Lee J, Lee ES, Kim DH, Lee ES, Choi HG, Chang HW, Jahng Y. 2004. Characterization of in vitro metabolites of rutaecarpine in rat liver microsomes using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 18: 1073-1080.
18. 4 and structurally related conjugates. J Biol Chem 269: 27807-27810.
19. Lennernas H, Palm K, Fagerholm U, Artursson P. 1996. Comparison between active and passive drug transport in human intestinal epithelial (caco-2) cells in vitro and human jejunum in vivo. Int J Pharm 127: 103-107.
20. Noh EJ, Ahn KS, Shin EM, Jung SH, Kim YS. 2006. Inhibition of lipopolysaccharide-induced iNOS and COX-2 expression by dehydroevodiamine through suppression of NF-kappaB activation in RAW 264.7 macrophages. Life Sci 79: 695-701.
21. Peng YT, Shun AY, Tsai TH, Lin LC, Chen CF. 1993. High-performance liquid chromatography of the quinazolinocarboline alkaloid dehydroevodiamine. J Chromatogr 617: 87-93.
22. Rashid Z, Basson MD. 1996. Topoisomerase II inhibition differentially modulates Caco-2 intestinal epithelial cell pheno-type. Biochem Biophys Res Commun 219: 82-88.
23. Sharom FJ. 1997. The P-glycoprotein efflux pump: How does it transport drugs? J Membr Biol 160: 161-175.
24. Sugimoto T, Miyase T, Kuroyanagi T, Ueno A. 1988. Limonoids and quinolone alkaloids from Evodia rutaecarpa Benth. Chem Pharm Bull 36: 4453-4461.
25. Sumantran VN. 2007. Experimental approaches for studying uptake and action of herbal medicines. Phytother Res 21: 210-214.
26. Takahashi Y, Kondo H, Yasuda T, Watanabe T, Kobayashi SI, Yokohama S. 2002. Common solubilizers to estimate the Caco-2 transport of poorly water-soluble drugs. Int J Pharm 246: 85-94.
27. Tang YQ, Feng XZ, Huang L. 1996. Quinolone alkaloids from Evodia rutaecarpa. Phytochemistry 43: 719-722.
28. Teng J, Yang XW. 2006. Two new indoloquinazoline alkaloids from the unripe fruits of Evodia rutaecarpa. Heterocycles 68: 1691-1698.
29. Tian L, Yang XW, Wang Y, Xu W. 2007. Characteristics of uptake, transport and efflux of Z- and E-ajoenes in Caco-2 cell monolayers in vitro. Acta Pharm Sin 42: 87-92.
30. Tian XJ, Yang XD, Wang K, Yang XW. 2006. The efflux of flavonoids morin, isorhamnetin-3-O-rutinoside and diosmetin-7-O-β-D-xylopyranosyl-(1-6)- β-D-glucopyranoside in the human intestinal cell line Caco-2. Pharm Res 23: 1721-1728.
31. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. 1981. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 1967-1972.
32. Walgren RA, Karnaky Jr. KU, Lindenmayer GE, Walle T. 2000. Efflux of dietary flavonoid quercetin 4′-β-glucoside across human intestinal Caco-2 cell monolayers by apical multidrug resistance-associated protein-2. J Pharmacol Exp Ther 294: 830-836.
33. Walle UK, French KL, Walgren RA, Walle T. 1999. Transport of genistein-7-glucoside by human intestinal Caco-2 cells: Potential role for MRP2. Res Commun Mol Pathol Pharmacol 103: 45-56.
34. Wang HH, Chou CJ, Liao JF, Chen CF. 2001. Dehydroevodiamine attenuates beta-amyloid peptide-induced amnesia in mice. Eur J Pharmacol 413: 221-225.
35. Yang XW, Guo QM, Wang Y, Xu W, Tian L, Tian XJ. 2007. Intestinal permeability of antivirus constituents from the fruits of Eucalyptus globulus Labill. in Caco-2 Cell Model. Bioorg Med Chem Lett 17: 1107-1111.
36. Yee SY. 1997. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man-fact or myth. Pharm Res 14: 763-766.
37. 13C NMR chemical shifts of evodiamine, rutaecarpine and dehydroevodiamine. Chinese J Magn Reson 16: 563-568.